WEDNESDAY, Nov. 30 (HealthDay News) — Preliminary research suggests that a drug typically used to kickstart the immune system may help cancer patients who receive stem cell transplants and then develop a potentially deadly side effect.
California’s $3 billion stem cell program may ask voters for more state money to continue its work of turning research into new treatments and boosting the state’s economy in the process.
According to a new study by stem cell researchers, established human embryonic cell lines, including those approved for federal research funding under former President George W. Bush, are different than newly derived human embryonic stem cell lines. The …
The Sanford Consortium for Regenerative Medicine (SCRM), on Tuesday marked completion of the “Collaboratory,” a 150,700-square-foot biomedical research laboratory at 2880 Torrey Pines Scenic Drive. As part of the celebration the center is …
CLEVELAND, Nov. 30, 2011 /PRNewswire/ — University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance…just not as they originally thought. The “LateTIME” trial was a study of adult …
BACKGROUND: Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a …
Scientists say human blood stem cells can be engineered to develop in vivo into fully functional melanoma-killing lymphocytes. A multidisciplinary University of California Los Angeles (UCLA)-led team engineered human hematopoietic stem cells to …
On Nov. 4, 2008, Michigan voters passed Proposal 2, an amendment to the Michigan Constitution that allowed unused human embryos in the in vitro fertilization clinics to be destroyed and their embryonic stem cells (ESC) to be used for research …
Advanced Cell Technology, Inc. (”ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s director of business development, Matthew Vincent, Ph.D., will be presenting at the 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Nov. 30 to Dec. 1 in La Jolla, California.
At the Ottawa Hospital Research Institute, Michael Rudnicki is helping to chart the future of regenerative medicine. Dr. Rudnicki works with stem cells, a key to treatments and cures for a vast range of serious diseases. Dr. Rudnicki is head of the …